This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Dr Abel and and her colleagues are correct in pointing out that our article did not quantify the cost of diagnosing and treating skin cancers attributable to PUVA, the cost of reduced immune responsiveness, and the cost relating to possible cataract formation. Such costs were mentioned only because they were small compared with the costs of repeated PUVA treatments and the costs of hospitalizations for treatment of psoriasis. Furthermore, they were more than counterbalanced by the costs of alternative therapy (such as topical agents), lost time from work, and physician office fees.The ultimate place for PUVA in the treatment of psoriasis will depend on its long-term toxic effects. With the help of Dr Abel and other investigators, continued study for at least another five years of the original cohort of patients treated with PUVA should help provide a better assessment of long-term risks. However, it is not
Stern RS, Bleich HL, Fitzpatrick TB, Parrish JA. Cost-effectiveness of PUVA Therapy: Further Considerations-Reply. JAMA. 1982;247(13):1808–1809. doi:10.1001/jama.1982.03320380014009
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: